Physician profile
Erin S Redd
NPI 1578711586
$819.03
in general payments reported to CMS, 2019-2025
12 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.76 · 2022: $94.59 · 2023: $152 · 2024: $220 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.14 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.85 | 2022-2025 | |
| Incyte Corporation | $122.07 | 2021-2024 | Opzelura |
| Leo Pharma INC. | $115.90 | 2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $74.49 | 2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $64.52 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.25 | 2025 | Jublia, Cabtreo |
| Sun Pharmaceutical Industries INC. | $47.77 | 2022-2023 | Winlevi, Absorica Ld |
| Pfizer INC. | $46.66 | 2022-2024 | |
| Janssen Biotech, INC. | $40.01 | 2022-2023 | Tremfya |
| Verrica Pharmaceuticals INC. | $18.06 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $14.73 | 2024 | |
| Organon LLC | $4.72 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Redd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.